Baker Bros. Advisors BEIGF Position
Active5-Fund ConvergenceBaker Bros. Advisors held their position in BeOne Medicines Ltd. (BEIGF) in Q4 2025, holding $2.7B worth of shares across 8,799,053 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
BEIGF is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Zanidatamab in 108 days (Jul 31, 2026), making the timing of Baker Bros.'s position particularly relevant.
Baker Bros. Advisors BEIGF Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 8,799,053 | — | $2.7B |
| Q3 2025 | Held | 8,799,053 | — | $3.0B |
| Q2 2025 | Held | 8,799,053 | — | $2.1B |
| Q1 2025 | Decreased | 8,799,053 | -732,827 | $2.4B |
| Q4 2024 | Decreased | 9,531,880 | -1,037,017 | $1.8B |
| Q3 2024 | Held | 10,568,897 | — | $2.4B |
| Q2 2024 | Held | 10,568,897 | — | $1.5B |
| Q1 2024 | Held | 10,568,897 | — | $1.7B |
| Q4 2023 | Decreased | 10,568,897 | -1,100,000 | $1.9B |
| Q3 2023 | Held | 11,668,897 | — | $2.1B |
| Q2 2023 | Held | 11,668,897 | — | $2.1B |
| Q1 2023 | New | 11,668,897 | +11,668,897 | $2.5B |
Frequently Asked Questions
Does Baker Bros. Advisors own BEIGF?
Yes. As of Q4 2025, Baker Bros. Advisors holds 8,799,053 shares of BeOne Medicines Ltd. (BEIGF) valued at $2.7B. This data comes from their SEC 13F filing.
How many hedge funds own BEIGF?
5 specialist biotech hedge funds currently hold BEIGF, including Boxer Capital, Driehaus Capital, Tang Capital Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy BEIGF?
Baker Bros. Advisors's position in BEIGF was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's BEIGF position increasing or decreasing?
Baker Bros. Advisors held their BEIGF position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BEIGFCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →